Classifications

• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/13—Amines
  • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P3/00—Drugs for disorders of the metabolism
  • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
  • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Definitions

• the present invention relates to compositions and methods for treating metabolic syndrome and conditions associated therewith. More specifically, the present invention relates to the use of compositions comprising clomiphene enriched for /r ⁇ ms-clomiphene for treating metabolic syndrome and conditions associated therewith in subjects with low or low normal testosterone. The present invention also relates to the use of compositions comprising clomiphene enriched for trans-clomiphene for treating diabetes mellitus type 2.
• Metabolic syndrome is characterized by a group of metabolic risk factors in one person including abdominal obesity, insulin resistance or glucose intolerance, atherogenic dyslipidemia, prothrombotic state, proinflammatory state and hypertension.
• the Adult Treatment Panel defines metabolic syndrome as present if a patient manifests at least three of the following symptoms: waist measuring at least 40 inches for men, 35 inches for women; serum triglyceride levels of at least 150 mg/dl; HDL cholesterol levels of less than 40 mg/dl in men, less than 50 mg/dl in women, blood pressure of at least 135/80 mm Hg and blood sugar (serum glucose) of at least 110 mg/dl. It has been estimated that up to 25% of the population in the United States are afflicted with metabolic syndrome.
• metabolic syndrome An underlying cause of metabolic syndrome is believed to be insulin resistance wherein the ability of insulin to take in glucose from the blood is attenuated. This causes glucose levels to remain elevated after eating to which the pancreas responds by excreting insulin. If left untreated, metabolic syndrome significantly increases the risk of type II diabetes, cardiovascular disease and other diseases related to plaque buildups in artery walls.
• An inverse correlation between fasting insulin levels and serum testosterone in men has been demonstrated by several studies. Moreover, serum testosterone is significantly lower in men with metabolic syndrome and other insulin-resistant states such as obesity and type 2 diabetes mellitus compared to controls. The mechanism underlying these observations, however, has not been elucidated.
• Testosterone is the primary male androgen, playing a vital role in overall male health. Testosterone is essential to the development and maintenance of specific reproductive tissues (testes, prostate, epididymis, seminal vesicle, and penis) and male secondary sex characteristics. It plays a key role in libido and erectile function and is necessary for the initiation and maintenance of spermatogenesis.
• Testosterone secretion is the end product of a series of hormonal processes.
• Gonadotropin-releasing hormone GnRH
• LH luteinizing hormone
• FSH follicle stimulating hormone
• Testosterone deficiency can result from underlying disease or genetic disorders and is also frequently a complication of aging.
• primary hypogonadism results from primary testicular failure.
• testosterone levels are low and levels of pituitary gonadotropins (LH and FSH) are elevated.
• Secondary or hypogonadotrophic hypogonadism is due to inadequate secretion of the pituitary gonadotropins.
• LH and FSH levels are low or low-normal.
• Clomiphene (FIG. 2), which is an antiestrogen related to tamoxifen, has also been used to treat men with low testosterone levels. Clomiphene blocks the normal estrogen feedback on the hypothalamus and subsequent negative feedback on the pituitary. This leads to increases in luteinizing hormone (LH) and follicle stimulating hormone (FSH). In men, these increased levels of gonadotropins stimulate the Leydig cells of the testes and result in the production of higher testosterone levels.
• LH luteinizing hormone
• FSH follicle stimulating hormone
• clomiphene is a mixture of two geometric isomers which they refer to as cis,-Z-, clomiphene (cw-clomiphene or zuclomiphene) and trans-,E-, clomiphene, (/ram-clomiphene or enclomiphene).
• clomiphene HCI has a melting point of 149 0 C-150.5 0 C
• c ⁇ -clomiphene HCI has a melting point of 156.5°C-158°C.
• the tmns-isomer is antiestrogenic (AE) while the cis-isomer is the more potent and more estrogenic form and has also been reported to have anti-estrogenic activity.
• the authors attribute the effect of the drug on ovulatory activity to both forms stating that the mixture is more effective than /rar ⁇ -clomiphene alone.
• the trans-homer aids ovulation at the level of the hypothalamus.
• the estrogenic isomer c ⁇ -clomiphene contributes to enhanced ovulation elsewhere in the physiologic pathway leading to ovulation.
• the isomers are also reported to have different in vivo half-life.
• the cis form has been reported to leave residual blood levels for in excess of one month following a single dose.
• Clomiphene is currently approved as a mixture of both cis- and /r ⁇ ra-isomers, the cis- isomer being present as about 30% to 50% (Merck Manual) for fertility enhancement in the anovulatory patient.
• Clomiphene improves ovulation by initiating a series of endocrine events culminating in a preovulatory gonadotropin surge and subsequent follicular rupture.
• the drug is recommended to be administered for 5 days at a dose of up to 100 mg daily.
• Clomiphene has also been associated with numerous side effects including: blurred vision, abdominal discomfort, gynecomastia, testicular tumors, vasomotor flushes, nausea, and headaches.
• the present invention is related to a method of treating metabolic syndrome comprising administering to a subject in need thereof, a composition comprising an effective amount of an antiestrogen or a pharmaceutically acceptable salt thereof.
• the subject may be male or female.
• the subject may also have idiopathic or secondary hypogonadotrophic hypogonadism.
• the present invention is also related to a method of treating metabolic syndrome in a subject comprising administering to a subject in need thereof, an effective amount of a composition comprising 0% to 29% weight/weight of (cis, -Z-, /r ⁇ r ⁇ -clomiphene) (hereinafter "c/s-clomiphene") and 100% to 71% w/w (trans-, E-, cw-clomiphene) (hereinafter "/r ⁇ r ⁇ -clomiphene”) or a pharmaceutically acceptable salt thereof.
• the composition may consist essentially of /r ⁇ / ⁇ -clomiphene or a salt thereof.
• the composition may also consist of /r ⁇ ra'-clomiphene or an analog thereof.
• the subject may be male or female.
• the subject may also have idiopathic or secondary hypogonadotrophic hypogonadism.
• the present invention is also related to a method of treating one or more symptoms of metabolic syndrome comprising administering to a subject in need thereof, a composition comprising an effective amount of an antiestrogen or a pharmaceutically acceptable salt thereof.
• the subject may be male or female.
• the subject may also have idiopathic or secondary hypogonadotrophic hypogonadism.
• the present invention is also related to a method for treating impaired fasting glucose in a subject comprising administering to a subject a composition comprising an effective amount of an antiestrogen or a pharmaceutically acceptable salt thereof.
• the subject may be male or female.
• the subject may be a male or female with a desire or need to reduce fasting glucose levels.
• the subject may also have idiopathic or secondary hypogonadotrophic hypogonadism.
• the present invention is also related to a method for treating impaired fasting glucose in a subject comprising administering to a subject a composition comprising 0% to 29% weight/weight of (cis, -Z-, rrara-clomiphene) (hereinafter "c «-clomiphene") and 100% to 71% w/w (trans-, E-, cw-clomiphene) (hereinafter "/rara'-clomiphene”) or a pharmaceutically acceptable salt thereof.
• the composition may consist essentially of frvmy-clomiphene or a salt thereof.
• the composition may also consist of /r ⁇ ra-clomiphene or an analog thereof.
• the subject may be a male or female with a desire or need to reduce serum glucose levels.
• the subject may also have idiopathic or secondary hypogonadotrophic hypogonadism [021]
• the present invention is also related to a method for treating diabetes mellitus type 2 in a subject comprising administering to a subject a composition comprising 0% to 29% weight/weight of (cis, -Z-, frvmy-clomiphene) (hereinafter "cw-clomiphene") and 100% to 71% w/w (trans-, E-, cw-clomiphene) (hereinafter "/r ⁇ ra-clomiphene”) or a pharmaceutically acceptable salt thereof.
• the composition may consist essentially of /ra/w-clomiphene or a salt thereof.
• composition may also consist of /rar ⁇ -clomiphene or an analog thereof.
• the subject may be a male or female with a desire or need to reduce serum glucose levels.
• the subject may also have idiopathic or secondary hypogonadotrophic hypogonadism.
• FIG. 1 is a graphic representative of the normal secretory total serum testosterone profiles in healthy men (young and old).
• FIG. 2 shows the chemical structure of clomiphene citrate.
• FIG. 3 is a graphic demonstration of the time course of serum testosterone levels
• Clomid (clomiphene citrate), Enclomid (/r ⁇ r ⁇ s-clomiphene) and Zuclomid (c/s-clomiphene).
• FIG. 4 is a graphic demonstration of the time course of cholesterol levels in baboon males treated with Clomid (clomiphene citrate), Enclomid (frr ⁇ -clomiphene) and Zuclomid
• FIG. 5 demonstrates the effect of AndroxalTM or Androgel® on testosterone levels.
• FIG. 6 demonstrates the effect of AndroxalTM or Androgel® on LH levels.
• FIG. 7 demonstrates the effect of AndroxalTM or Androgel® on FSH levels
• FIG. 8 demonstrates baseline blood glucose in AndroxalTM, Androgel® and placebo treatment groups.
• FIG. 9 demonstrates the effect of AndroxalTM on blood glucose levels.
• FIG. 10 demonstrates the effect of Androgel® on blood glucose levels.
• the present invention provides methods for treating metabolic syndrome and conditions associated therewith.
• the present invention also provides methods for treating diabetes mellitus type 2.
• the present invention is based in part on the surprising discovery that administration of a composition comprising trans-c ⁇ om ⁇ phene to subjects with low total testosterone causes a decrease in fasting serum glucose levels concomitant with an increase in testosterone levels and a decrease in cholesterol and triglyceride levels in the subjects.
• compositions comprising trans-clomiphene are surprisingly useful in treating metabolic syndrome.
• compositions comprising trans- clomiphene for treating diabetes mellitus type 2 is not limited to male subjects or to subjects having low testosterone.
• administration of a composition comprising an effective amount of an antiestrogen is used to treat metabolic syndrome in a subject in need of such treatment.
• the subject may be a male or female.
• the subject may also have idiopathic or secondary hypogonadotrophic hypogonadism.
• a composition comprising an effective amount of frr ⁇ zs-clomiphene or a predefined blend of the isomers of clomiphene as described below differing from the normally produced mixture, is used to treat metabolic syndrome in a male or female subject.
• metabolic syndrome relates to metabolic syndrome as defined by the Adult Treatment Panel or any other recognized definition of this syndrome. Synonyms for "metabolic syndrome” used in the art include Reaven's Syndrome, Insulin Resistance Syndrome and Syndrome X. It is to be understood that where the term “metabolic syndrome” is used herein it also refers to Reaven's Syndrome, Insulin Resistance Syndrome and Syndrome X.
• administration of a composition comprising an effective amount of an antiestrogen, preferably /r ⁇ my-clomiphene, is used to treat a symptom of metabolic syndrome in a subject in need of such treatment.
• the symptom of metabolic syndrome may include, without limitation, elevated glucose levels, elevated triglyceride levels, elevated cholesterol levels, insulin resistance, high blood pressure, abdominal obesity, prothrombotic state, proinflammatory state, or any combination of two or more symptoms.
• the subject may be male or female.
• the subject may also have idiopathic or secondary hypogonadotrophic hypogonadism.
• compositions comprising an effective amount of an antiestrogen, preferably ?r ⁇ my-clomiphene, to a subject with metabolic syndrome may be combined with any known treatment regimen.
• known treatment regimens for metabolic syndrome include, without limitation, exercise regimens, weight reduction regimens, blood pressure medications such as ACE inhibitors, cholesterol reducing medications, and metformin.
• Compositions of the invention may be simultaneously, separately or sequentially administered with any of the aforementioned known treatment regimens.
• administration of a composition comprising an effective amount of an antiestrogen is used to treat impaired fasting glucose in a subject.
• the subject may be male or female.
• the subject may have idiopathic or secondary hypogonadotrophic hypogonadism.
• compositions of the instant invention may be administered to a subject with fasting blood glucose levels between 1 10 mg/dl and 125 mg/dl.
• the subject may have a fasting blood glucose level of 110, 11 1, 1 12, 113, 1 14, 1 15, 116, 117, 1 18, 1 19, 120, 121, 122, 123, 124, or 125 mg/dl.
• compositions of the invention may decrease fasting blood glucose levels to below 125, 124, 123, 122, 121, 120, 1 19, 1 18, 117, 1 16, 115, 114, 113, 1 12, 1 1 1 and preferably below 1 10 mg/dl.
• the present invention provides a method for preventing the transition from impaired fasting glucose to diabetes mellitus type 2 in a subject comprising the administration to the subject of a composition comprising an effective amount of an antiestrogen, preferably /r ⁇ r ⁇ -clomiphene.
• the subject may be male or female.
• the subject may also have idiopathic or secondary hypogonadal hypogonadism.
• a patient with idiopathic or secondary hypogonadotrophic hypogonadism with a need or desire to lower fasting blood glucose levels is administered a composition comprising an effective amount of an antiestrogen, preferably /raras-clomiphene.
• the hypogonadal patient may have any fasting glucose level, but preferably has a fasting glucose level above about 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 1 1 1, 1 12, 1 13, 1 14, 1 15, 1 16, 1 17, 1 18, 1 19, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 134, 135, 136, 137, 138, 139, 140, 141, 142, 143, 144, 145, 146, 147, 148, 149, 150, 151, 152, 153, 154, 155, 160, 165, 170, 175, 180, 185, 190, 195, or 200 mg/dl.
• the hypogonadal patient may have fasting glucose levels between 125 and 140 mg/dl.
• the composition may comprise an amount of an antiestrogen, preferably /r ⁇ ra r -clomiphene, to lower the hypogonadal patient's fasting glucose level below 200, 195, 190, 185, 180, 175, 170, 165, 160, 155, 154, 153, 152, 151, 150, 149, 148, 147, 148, 147, 146, 145, 144, 143, 142, 141, 140, 139, 138, 137, 136, 135, 134, 133, 132, 131, 130, 129, 128, 127, 126, 125, 124, 123, 122, 121, 120, 1 19, 1 18, 117, 116, 115, 114, 113, 112, 111 or preferably below 110 mg/dl.
• the patient may also be diagnosed with diabetes mellitus type 2.
• the present invention also provides a method for treating diabetes mellitus type 2 comprising administering to a subject in need thereof, a composition comprising an effective amount of an antiestrogen.
• the antiestrogen is /r ⁇ m'-clomiphene or a pharmaceutically acceptable salt thereof.
• the subject may be male or female.
• the subject may have idiopathic or secondary hypogonadotrophic hypogonadism.
• compositions of the invention may be may be combined with any known treatment regimen for diabetes mellitus type 2.
• Known treatment regimens for diabetes mellitus type 2 include, without limitation: exercise regimens; weight reduction regimens; blood pressure medications such as angiotensin- converting enzyme (ACE) inhibitors (e.g. ramipril); metformin; thiazolidinediones (TZDs); ⁇ -glucosidase inhibitors such as acarbose and miglitol; meglitinides such as nateglinide, repaglinide; peptide analogs such as dipeptidyl peptidase-4 (DPP-4) inhibitors and amylin agonist analogs; and insulin.
• Compositions of the invention may be simultaneously, separately or sequentially administered with any of the aforementioned known treatment regimens.
• Subjects in need of treatment by any of the methods of the present invention may have low or low-normal total testosterone.
• male subjects in need of treatment may have total testosterone levels below about 320, 310, 300, 295, 290, 285, 280, 275, 270, 265, 260, 255, 250, 245, 240, 235, 230, 225, 220, 215, 210, 205, 200, 195, 190, 185, 180, 175, 170, 165, 160, 155, 150, 145, 140, 135, 130, 125, 120, 1 15, 105, 100, 95, 90, 85, 80, 75, 70, 65, 60, 55, 50, 45, 40, 35, 30, 25, 20, 15, 10 or 5 ng/dl.
• Male subjects with total testosterone below about 300 ng/dl are defined as hypogonadal.
• the present invention provides a method for treating adult onset idiopathic hypogonadotrophic hypogonadism (AIHH) or a condition associated therewith, comprising administering to a subject in need thereof an effective amount of a composition comprising an antiestrogen, preferably fr-a/w-clomiphene or a salt thereof.
• AIHH adult onset idiopathic hypogonadotrophic hypogonadism
• Men with AIHH are characterized as having both low testosterone and luteinizing hormone (LH) often accompanied by, inter alia, obesity and elevated blood glucose.
• Compositions of the invention may be useful in treating any of these conditions.
• a patient with idiopathic or secondary hypogonadotrophic hypogonadism who has developed metabolic syndrome is administered one or more dosages of an effective amount of a composition comprising trans- clomiphene at a dosage between one mg to about 200 mg (although the determination of optimal dosages is within the level of ordinary skill in the art) in order to treat metabolic syndrome or a condition associated therewith.
• C/s-clomiphene may also be present in the composition so long as the ratio of /rar ⁇ -clomiphene to cw-clomiphene is greater than 71/29.
• Analogs of the trans- and cis- isomers of clomiphene such as those described in Ernst, et al. supra are also useful in the practice of the present invention.
• Dosages are preferably (but not necessarily) administered as part of a dosage regimen designed to give rise to serum testosterone levels that mimic or correspond to the normal secretary total serum testosterone profile described in FIG. 1 during the period of administration and preferably during the period of discontinuance as well.
• a dosage of the preferred composition may be administered in a pharmaceutical formulation that would give rise to peak serum testosterone levels at around 8 a.m.
• Such pharmaceutical formulations may be in the form of sustained release formulations prepared as described for example in U.S. Patent No. 6,221 ,399, Japanese patent 4-312522, Meshali et al, Int. J. Phar. 89: 177-181 (1993), Kharenko et al, Intern. Symp. Control ReI.
• the dosage of frww-clomphene may be from 5 to 100 mg.
• the dosage of trans- clomphene may also be from 12.5 to 50 mg.
• the dosage of /r ⁇ / ⁇ -clomphene may also be 12.5 mg , 25 mg or 50 mg.
• beneficial or desired clinical results include, but are not limited to, alleviation of symptoms, diminishment of extent of disease, stabilized (i.e., not worsening) state of disease, delay or slowing of disease progression, amelioration or palliation of the disease state and remission (whether partial or total), whether detectable or undetectable.
• Treatment can also mean prolonging survival as compared to expected survival if not receiving treatment. Individuals in need of treatment include those already with the condition or disorder as well as those prone to develop the condition or disorder or those in whom the condition or disorder is to be prevented.
• modulate refers to both therapeutic treatment and prophylactic or preventative measures, wherein the object is to prevent or slow down (lessen) an undesired clinical parameter.
• beneficial or desired clinical results include, but are not limited to, correcting of clinical parameter, diminishment of extent of clinical parameter, stabilized (i.e., not worsening) clinical parameter and delay or slowing of extent of clinical parameter.
• antiestrogen it is meant a compound that prevents estrogens from expressing their effects on estrogen dependent target tissues consequently antagonizing a variety of estrogen-dependent processes.
• antiestrogenic trans- clomiphene isomer is effective in lowering serum glucose levels in hypogonadal subjects, it is expected that any compound with antiestrogenic activity will be useful in the present invention.
• antiestrogens useful in the practice of the instant invention are those capable of blocking the action of estrogen.
• Antiestrogens useful in the practice of the instant invention may be pure antiestrogens or may have partial estrogenic action as in the case of the selective estrogen receptor modulators (SERMs) which exhibit antiestrogenic properties in some tissues and estrogenic tissues in others.
• SERMs selective estrogen receptor modulators
• Pure antiestrogens of the invention include, without limitation: RU 58,688, described in Van de Velde et al, Ann. NY Acad. Sci., 761(3):164-175 (1995); 13-methyl-7-[9- (4,4,5,5, 5-pentafluoropentylsulfinyl)nonyl]-7,8,9, 1 1 , 12, 13, 14, 15, 16, 17-decahydro-6H- cyclopenta[a]-phenanthrene-3, 17-diol (ICI 182,780/fulvestrant) and other compounds described in EP 0138504; N-butyl-l l-[(7R,8S,9S, 13S,14S,17S)-3,17-dihydroxy-13-methyl- 6,7,8,9, 1 1,12,14,15,16,17-decahydrocyclopena[a]phenanthren-7-yl]-N-methyl-undecanamide (ICI 164,384), described in Wakeling
• SERMs of the invention include, without limitation, triphenylalkylenes such as triphenylethylenes, which include: 2-[4-(l,2-diphenylbut-l-enyl)phenoxy]-N,N-dimethyl- ethanamine (tamoxifen) and other compounds described in U.S. Patent No. 4,536,516, incorporated herein by reference; Trans-4-(l-(4-(2-dimethylamino)ethoxy)phenyl)-2-phenyl- l-butenyl)phenol (4-hydroxytamoxifen) and other compounds described in U.S. Patent No.
• SERMS of the invention also include, without limitation, benzothiphene derivatives such as: [6-hydroxy-2-(4-hydroxyphenyl)-benzothiophen-3-yl]-[4-[2-(l- piperidinyl)ethoxy)phenyl]-methanone (raloxifene) and other compounds described in U.S. Patent Nos.
• chromans such as 3,4-trans-2,2-dimethyl-3-phenyl-4-[4-(2- (2-(pyrrolidin-l-yl)ethoxy)phenyl]-7-methoxychroman (levormeloxifene) and other compounds described in WO 97/25034, WO 97/25035, WO 97/25037 and WO 97/25038; and l-(2-((4-(-methoxy-2,2, dimethyl-3-phenyl-chroman-4-yl)-phenoxy)-ethyl)-pyrrolidine (centchroman) and other compounds described in U.S. Patent No. 3,822,287, incorporated herein by reference.
• SERMs of the invention include, without limitation, the compounds described in U.S. Patent Nos. 6,387,920, 6,743,815, 6,750,213, 6,869,969, 6,927,224, 7,045,540, 7, 138,426, 7, 151,196, and 7,157,604, each of which is incorporated herein by reference.
• antiestrogens of the invention include: 6 ⁇ -chloro-16 ⁇ -methyl- pregn-4-ene-3,20-dione (clometherone); 6-chloro-17-hydroxypregna-l,4,6-triene-3,20-dione (delmadinone); l-[2-[4-[l-(4-methoxyphenyl)-2-nitro-2-phenylethenyl]phenoxy]ethyl]- pyrrolidine (nitromifene/CN-55,945-27); and l-[2-[p-(3,4-Dihydro-6-methoxy-2-phenyl-l- naphthyl)phenoxy]ethyl]pyrrolidine (nafoxidene).
• antiestrogens of the invention include indoles such as those disclosed in J. Med. Chem., 33:2635-2640 (1990), J. Med. Chem., 30: 131-136 (1987), WO 93/10741, WO 95/17383, WO 93/23374 and U.S. Patent Nos. 6,503,938 and 6,069,153, both of which are incorporated herein by reference.
• antiestrogens of the invention include 2-[3-(l-cyano-l-methyl- ethyl)-5-(lH-l,2,4-triazol-l-ylmethyl)phenyl]-2-methyl-propanenitrile (anastrozole) and other compounds described in EP 0296749; 6-Methylenandrosta-l,4-diene-3,17-dione (exemestane) and other compounds described in U.S. Patent No. 4,808,616, incorporated herein by reference; 4-[(4-cyanophenyl)-(l,2,4-triazol-l-yl)methyl]benzonitrile (letrozole) and other compounds described in U.S. Patent No.
• Patent 5,047,431 incorporated herein by reference; 2 ⁇ ,3 ⁇ -Epithio-5 ⁇ -androstan-17 ⁇ -ol (epitiostanol); 2 ⁇ ,3 ⁇ -Epitio-5 ⁇ - androstane-17 ⁇ -yl-l-methoxycyclopentyloxy (mepitiostane); 4-[(2Z,4Z)-4-(4- hydroxyphenyl)hexa-2,4-dien-3-yl]phenol (cycladiene) and other compounds described in U.S. Pat. Nos.
• Still other antiestrogens of the invention include, without limitation: (2e)-3-(4-((l e)- l,2-diphenylbut-l-enyl)phenyl)acrylic acid (GW5638), GW7604 and other compounds described in Wilson et al., Endocrinology, 138(9):3901-391 1 (1997) and WO 95/10513; l-[4- (2-diethylaminoethoxy)phenyl]-2-(4-methoxyphenyl)-l-phenyl-ethanol (MER-25), N,N- diethyl-2-[4-(5-methoxy-2-phenyl-3H-inden-l-yl)phenoxy]ethanamine hydrochloride (U- 1 1,555A), l-[2-[4-(6-methoxy-2-phenyl-3,4-dihydronaphthalen-l- yl)phenoxy]ethyl]pyrrolidine hydrochloride
• Still other antiestrogens of the invention include, without limitation: non-steroidal estrogen receptor ligands such as those described in U.S. Patent Nos. 5,681,835, 5,877,219, 6,207,716, 6,340,774 and 6,599,921, each of which is incorporated herein by reference; steroid derivatives such as those described in U.S. Patent No.
• compositions of the invention comprise one or more antiestrogens or pharmaceutically acceptable salts thereof.
• the salt compound obtained may be either in neutral or salt form. Salt forms include hydrates and other solvates and also crystalline polymorphs. Both the free base and the salts of these end products may be used in accordance with the invention.
• Acid addition salts may in a manner known per se be transformed into the free base using basic agents such as alkali or by ion exchange. The free base obtained may also form salts with organic or inorganic acids.
• acids which form suitably pharmaceutically acceptable salts.
• examples of such acids are hydrochloric acid, sulfuric acid, phosphoric acid, nitric acid, aliphatic acid, alicyclic carboxylic or sulfonic acids, such as formic acid, acetic acid, propionic acid, succinic acid, glycolic acid, lactic acid, malic acid, tartaric acid, citric acid, ascorbic acid, glucuronic acid, fumaric acid, maleic acid, hydroxymaleic acid, pyruvic acid, aspartic acid, glutamic acid, p-hydroxybenzoic acid, embonic acid, ethanesulfonic acid, hydroxyethanesulfonic acid, phenylacetic acid, mandelic acid, alogenbensenesulfonic acid, toluenesulfonic acid, galactaric acid, galacturonic acid or naphthalenesulfonic acid. All crystalline form
• Base addition salts may also be used in accordance with the invention and may be prepared by contacting the free acid form with a sufficient amount of the desired base to produce the salt in the conventional manner.
• the free acid form may be regenerated by contacting the salt form with an acid and isolating the free acid in the conventional manner.
• Pharmaceutically acceptable base addition salts are formed with metals or amines, such as alkali and alkali earth metals or organic amines. Examples of metals used as cations are sodium, potassium, calcium, magnesium and the like. Examples of suitable amines are amino acids such as lysine, choline, diethanolamine, ethylenediamine, N-methylglucamine and the like.
• compositions of the instant invention can be prepared in the form of a dose unit or dose units suitable for oral, parenteral, transdermal, rectal, transmucosal, or topical administration.
• Parenteral administration includes, but is not limited to, intravenous, intraarterial, intraperitoneal, subcutaneous, intramuscular, intrathecal, and intraarticular.
• oral administration or “orally deliverable” herein include any form of delivery of a therapeutic agent or a composition thereof to a subject wherein the agent or composition is placed in the mouth of the subject, whether or not the agent or composition is swallowed.
• oral administration includes buccal and sublingual as well as esophageal (e.g. inhalation) administration.
• compositions of the present invention are formulated as rectal suppositories, which may contain suppository bases including, but not limited to, cocoa butter or glycerides.
• compositions of the present invention may also be formulated for inhalation, which may be in a form including, but not limited to, a solution, suspension, or emulsion that may be administered as a dry powder or in the form of an aerosol using a propellant, such as dichlorofuoromethane or trichlorofluoromethane.
• a propellant such as dichlorofuoromethane or trichlorofluoromethane.
• compositions of the present invention may also be formulated for transdermal delivery, for example as a cream, ointment, lotion, paste, gel, medicated plaster, patch, or membrane.
• Such compositions can comprise any suitable excipients, for example penetration enhancers and the like.
• compositions of the present invention may also be formulated for parenteral administration including, but not limited to, by injection or continuous infusion.
• Formulations for injection may be in the form of suspensions, solutions, or emulsions in oily or aqueous vehicles. Such compositions may also be provided in powder form for reconstitution with a suitable vehicle including, but not limited to, sterile, pyrogen-free water,
• compositions of the present invention may also be formulated as a depot preparation, which may be administered by implantation or by intramuscular injection.
• Such compositions may be formulated with suitable polymeric or hydrophobic materials (as an emulsion in an acceptable oil, for example), ion exchange resins, or as sparingly soluble derivatives (as a sparingly soluble salt, for example).
• compositions of the present invention may also be formulated as a liposome preparation.
• Liposome preparations can comprise liposomes which penetrate the cells of interest or the stratum corneum and fuse with the cell membrane resulting in delivery of the contents of the liposome into the cell.
• liposomes such as those described in
• Patent No. 4,508,703 to Redziniak et al. can be used.
• a composition of the invention can be in the form of solid dosage units such as tablets, (e.g. suspension tablets, bite suspension tablets, rapid dispersion tablets, chewable tablets, effervescent tablets, bi layer tablets, etc.), caplets, capsules ⁇ e.g., a soft or a hard gelatin capsule), powder ⁇ e.g. a packaged powder, a dispensable powder or an effervescent powder), lozenges, sachets, cachets, troches, pellets, granules, microgranules, encapsulated microgranules, powder aerosol formulations, or any other solid dosage form reasonably adapted for administration.
• tablets e.g. suspension tablets, bite suspension tablets, rapid dispersion tablets, chewable tablets, effervescent tablets, bi layer tablets, etc.
• caplets ⁇ e.g., a soft or a hard gelatin capsule
• powder ⁇ e.g. a packaged powder, a dispensable powder or an effervescent powder
• Tablets can be prepared according to any of the many relevant, well known pharmacy techniques.
• tablets or other solid dosage forms can be prepared by processes that employ one or a combination of methods including, without limitation, (1) dry mixing, (2) direct compression, (3) milling, (4) dry or non-aqueous granulation, (5) wet granulation, or (6) fusion.
• the individual steps in the wet granulation process of tablet preparation typically include milling and sieving of the ingredients, dry powder mixing, wet massing, granulation and final grinding.
• Dry granulation involves compressing a powder mixture into a rough tablet or "slug" on a heavy-duty rotary tablet press. The slugs are then broken up into granular particles by a grinding operation, usually by passage through an oscillation granulator.
• the individual steps include mixing of the powders, compressing (slugging) and grinding (slug reduction or granulation). Typically, no wet binder or moisture is involved in any of the steps.
• solid dosage forms can be prepared by mixing an antiestrogen with one or more pharmaceutical excipients to form a substantially homogenous preformulation blend.
• the preformulation blend can then be subdivided and optionally further processed (e.g. compressed, encapsulated, packaged, dispersed, etc.) into any desired dosage forms.
• Compressed tablets can be prepared by compacting a powder or granulation composition of the invention.
• the term “compressed tablet” generally refers to a plain, uncoated tablet suitable for oral ingestion, prepared by a single compression or by pre- compaction tapping followed by a final compression. Tablets of the present invention may be coated or otherwise compounded to provide a dosage form affording the advantage of improved handling or storage characteristics. In one embodiment, any such coating will be selected so as to not substantially delay onset of therapeutic effect of a composition of the invention upon administration to a subject.
• sustained tablet refers to a compressed tablet that rapidly disintegrates after placement in water.
• Suitable liquid dosage forms of a composition of the invention include solutions, aqueous or oily suspensions, elixirs, syrups, emulsions, liquid aerosol formulations, gels, creams, ointments, etc. Such compositions may also be formulated as a dry product for constitution with water or other suitable vehicle before use.
• liquid or semi-solid compositions upon storage in a closed container maintained at either room temperature, refrigerated (e.g. about 5 -10 0 C) temperature, or freezing temperature for a period of about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 1 1, or 12 months, exhibit at least about 90%, at least about 92.5%, at least about 95%, or at least about 97.5% of the original antiestrogen compound present therein.
• compositions of the invention can, if desired, include one or more pharmaceutically acceptable excipients.
• excipient herein means any substance, not itself a therapeutic agent, used as a carrier or vehicle for delivery of a therapeutic agent to a subject or added to a pharmaceutical composition to improve its handling or storage properties or to permit or facilitate formation of a unit dose of the composition.
• Excipients include, by way of illustration and not limitation, diluents, disintegrants, binding agents, adhesives, wetting agents, lubricants, glidants, surface modifying agents or surfactants, fragrances, suspending agents, emulsifying agents, nonaqueous vehicles, preservatives, antioxidants, adhesives, agents to adjust pH and osmolarity (e.g. buffering agents), preservatives, thickening agents, sweetening agents, flavoring agents, taste masking agents, colorants or dyes, penetration enhancers and substances added to improve appearance of the composition.
• Excipients optionally employed in compositions of the invention can be solids, semisolids, liquids or combinations thereof.
• Compositions of the invention containing excipients can be prepared by any known technique of pharmacy that comprises mixing an excipient with a drug or therapeutic agent.
• compositions of the invention optionally comprise one or more pharmaceutically acceptable diluents as excipients.
• suitable diluents illustratively include, either individually or in combination, lactose, including anhydrous lactose and lactose monohydrate; starches, including directly compressible starch and hydrolyzed starches (e.g., CelutabTM and EmdexTM); mannitol; sorbitol; xylitol; dextrose (e.g., CereloseTM 2000) and dextrose monohydrate; dibasic calcium phosphate dihydrate; sucrose-based diluents; confectioner's sugar; monobasic calcium sulfate monohydrate; calcium sulfate dihydrate; granular calcium lactate trihydrate; dextrates; inositol; hydrolyzed cereal solids; amylose; celluloses including microcrystalline cellulose, food grade sources of ⁇ - and amorphous cellulose (e.
• Such diluents if present, constitute in total about 5% to about 99%, about 10% to about 85%, or about 20% to about 80%, of the total weight of the composition. Any diluent or diluents selected preferably exhibit suitable flow properties and, where tablets are desired, compressibility.
• extragranular microcrystalline cellulose that is, microcrystalline cellulose added to a wet granulated composition after a drying step
• hardness for tablets
• disintegration time for disintegration time
• compositions of the invention optionally comprise one or more pharmaceutically acceptable disintegrants as excipients, particularly for tablet, capsule or other solid formulations.
• Suitable disintegrants include, either individually or in combination, starches, including sodium starch glycolate (e.g., ExplotabTM of Pen West) and pregelatinized corn starches (e.g., NationalTM 1551, NationalTM 1550, and ColocornTM 1500), clays (e.g., VeegumTM HV), celluloses such as purified cellulose, microcrystalline cellulose, methylcellulose, carboxymethylcellulose and sodium carboxymethylcellulose, croscarmellose sodium (e.g., Ac-Di-SolTM of FMC), alginates, crospovidone, and gums such as agar, guar, xanthan, locust bean, karaya, pectin and tragacanth gums.
• starches including sodium starch glycolate (e.g., ExplotabTM of Pen West) and pregelatinized corn star
• Disintegrants may be added at any suitable step during the preparation of the composition, particularly prior to a granulation step or during a lubrication step prior to compression. Such disintegrants, if present, constitute in total about 0.2% to about 30%, about 0.2% to about 10%, or about 0.2% to about 5%, of the total weight of the composition.
• Compositions of the invention optionally comprise one or more pharmaceutically acceptable binding agents or adhesives as excipients, particularly for tablet formulations. Such binding agents and adhesives preferably impart sufficient cohesion to the powder being tableted to allow for normal processing operations such as sizing, lubrication, compression and packaging, but still allow the tablet to disintegrate and the composition to be absorbed upon ingestion.
• Suitable binding agents and adhesives include, either individually or in combination, acacia; tragacanth; sucrose; gelatin; glucose; starches such as, but not limited to, pregelatinized starches (e.g., NationalTM 151 1 and NationalTM 1500); celluloses such as, but not limited to, methylcellulose and carmellose sodium (e.g., TyloseTM); alginic acid and salts of alginic acid; magnesium aluminum silicate; PEG; guar gum; polysaccharide acids; bentonites; povidone, for example povidone K-15, K-30 and K-29/32; polymethacrylates; HPMC; hydroxypropylcellulose (e.g., KlucelTM); and ethylcellulose (e.g., EthocelTM).
• acacia tragacanth
• sucrose gelatin
• glucose starches
• starches such as, but not limited to, pregelatinized starches (e.g., NationalTM 151 1 and NationalTM 1500
• compositions of the invention optionally comprise one or more pharmaceutically acceptable wetting agents as excipients.
• Non-limiting examples of surfactants that can be used as wetting agents in compositions of the invention include quaternary ammonium compounds, for example benzalkonium chloride, benzethonium chloride and cetylpyridinium chloride, dioctyl sodium sulfosuccinate, polyoxyethylene alkylphenyl ethers, for example nonoxynol 9, nonoxynol 10, and octoxynol 9, poloxamers (polyoxyethylene and polyoxypropylene block copolymers), polyoxyethylene fatty acid glycerides and oils, for example polyoxyethylene (8) caprylic/capric mono- and diglycerides (e g., LabrasolTM of Gattefosse), polyoxyethylene (35) castor oil and polyoxyethylene (40) hydrogenated castor oil; polyoxyethylene alkyl ethers, for example polyoxyethylene (20) cetostearyl ether, polyoxyethylene fatty acid esters, for example polyoxyethylene (40) stearate, poly
• compositions of the invention optionally comprise one or more pharmaceutically acceptable lubricants (including anti-adherents and/or glidants) as excipients.
• Suitable lubricants include, either individually or in combination, glyceryl behapate (e.g., CompritolTM 888); stearic acid and salts thereof, including magnesium (magnesium stearate), calcium and sodium stearates; hydrogenated vegetable oils (e.g., SterotexTM); colloidal silica; talc; waxes; boric acid; sodium benzoate; sodium acetate; sodium fumarate; sodium chloride; DL-leucine; PEG (e.g., CarbowaxTM 4000 and CarbowaxTM 6000); sodium oleate; sodium lauryl sulfate; and magnesium lauryl sulfate.
• Such lubricants if present, constitute in total about 0.1% to about 10%, about 0.2% to about 8%, or about 0.25% to about 5%, of the total weight of the composition.
• Suitable anti-adherents include talc, cornstarch, DL-leucine, sodium lauryl sulfate and metallic stearates.
• Talc is an anti-adherent or glidant used, for example, to reduce formulation sticking to equipment surfaces and also to reduce static in the blend.
• One or more anti-adherents, if present, constitute about 0.1% to about 10%, about 0.25% to about 5%, or about 0.5% to about 2%, of the total weight of the composition.
• Glidants can be used to promote powder flow of a solid formulation. Suitable glidants include colloidal silicon dioxide, starch, talc, tribasic calcium phosphate, powdered cellulose and magnesium trisilicate.
• compositions of the present invention can comprise one or more anti-foaming agents.
• Simethicone is an illustrative anti-foaming agent.
• Anti-foaming agents, if present, constitute about 0.001% to about 5%, about 0.001% to about 2%, or about 0.001 % to about 1%, of the total weight of the composition.
• compositions of the invention can comprise a preservative.
• Suitable preservatives include, but are not limited to, benzalkonium chloride, methyl, ethyl, propyl or butylparaben, benzyl alcohol, phenylethyl alcohol, benzethonium, methyl or propyl p-hydroxybenzoate and sorbic acid or combinations thereof.
• the optional preservative is present in an amount of about 0.01% to about 0.5% or about 0.01% to about 2.5%, by weight.
• compositions of the invention optionally comprise a buffering agent.
• Buffering agents include agents that reduce pH changes.
• Illustrative classes of buffering agents for use in various embodiments of the present invention comprise a salt of a Group IA metal including, for example, a bicarbonate salt of a Group IA metal, a carbonate salt of a Group IA metal, an alkaline or alkali earth metal buffering agent, an aluminum buffering agent, a calcium buffering agent, a sodium buffering agent, or a magnesium buffering agent.
• Suitable buffering agents include carbonates, phosphates, bicarbonates, citrates, borates, acetates, phthalates, tartrates, succinates of any of the foregoing, for example sodium or potassium phosphate, citrate, borate, acetate, bicarbonate and carbonate.
• Non-limiting examples of suitable buffering agents include aluminum, magnesium hydroxide, aluminum glycinate, calcium acetate, calcium bicarbonate, calcium borate, calcium carbonate, calcium citrate, calcium gluconate, calcium glycerophosphate, calcium hydroxide, calcium lactate, calcium phthalate, calcium phosphate, calcium succinate, calcium tartrate, dibasic sodium phosphate, dipotassium hydrogen phosphate, dipotassium phosphate, disodium hydrogen phosphate, disodium succinate, dry aluminum hydroxide gel, magnesium acetate, magnesium aluminate, magnesium borate, magnesium bicarbonate, magnesium carbonate, magnesium citrate, magnesium gluconate, magnesium hydroxide, magnesium lactate, magnesium metasilicate aluminate, magnesium oxide, magnesium phthalate, magnesium phosphate, magnesium silicate, magnesium succinate, magnesium tartrate, potassium acetate, potassium carbonate, potassium bicarbonate, potassium borate, potassium citrate, potassium metaphosphate, potassium phthalate, potassium phosphate, potassium phosphat
• compositions the invention may include one or more agents that increase viscosity.
• agents that increase viscosity include, but are not limited to, methylcellulose, carboxymethylcellulose sodium, ethylcellulose, carrageenan, carbopol, and/or combinations thereof.
• one or more viscosity increasing agents are present in compositions of the invention in an amount of about 0.1% to about 10%, or about 0.1% to about 5%, by weight.
• compositions of the invention comprise an "organoleptic agent" to improve the organoleptic properties of the composition.
• organoleptic agent refers to any excipient that can improve the flavor or odor of, or help mask a disagreeable flavor or odor of a composition of the invention.
• agents include sweeteners, flavoring agents and/or taste masking agents.
• Suitable sweeteners and/or flavoring agents include any agent that sweetens or provides flavor to a pharmaceutical composition.
• Optional organoleptic agents are typically present in a composition of the invention in an amount of about 0.1 mg/ml to about 10 mg/ml, about 0.5 mg/ml to 5 mg/ml or about 1 mg/ml.
• Illustrative sweeteners or flavoring agents include, without limitation, acacia syrup, anethole, anise oil, aromatic elixir, benzaldehyde, benzaldehyde elixir, cyclodextrins, caraway, caraway oil, cardamom oil, cardamom seed, cardamom spirit, cardamom tincture, cherry juice, cherry syrup, cinnamon, cinnamon oil, cinnamon water, citric acid, citric acid syrup, clove oil, cocoa, cocoa syrup, coriander oil, dextrose, eriodictyon, eriodictyon fluidextract, eriodictyon syrup, aromatic, ethylacetate, ethyl vanillin, fennel oil, ginger, ginger fluidextract, ginger oleoresin, dextrose, glucose, sugar, maltodextrin, glycerin, glycyrrhiza, glycyr
• Illustrative taste masking agents include, but are not limited to, cyclodextrins, cyclodextrins emulsions, cyclodextrins particles, cyclodextrins complexes, or combinations thereof.
• Illustrative suspending agents include, but are not limited to, sorbitol syrup, methyl cellulose, glucose/sugar syrup, gelatin, hydroxyethylcellulose, carboxymethyl cellulose, aluminum stearate gel, and hydrogenated edible fats.
• Illustrative emulsifying agents include, but are not limited to, lecithin, sorbitan monooleate, and acacia.
• Nonaqueous vehicles include, but are not limited to, edible oils, almond oil, fractionated coconut oil, oily esters, propylene glycol, and ethyl alcohol.
• excipients can have multiple roles as is known in the art.
• starch can serve as a filler as well as a disintegrant.
• the classification of excipients above is not to be construed as limiting in any manner.
• compositions of the present invention may be administered in any manner including, but not limited to, orally, parenterally, sublingually, transdermally, rectally, transmucosally, topically, via inhalation, via buccal administration, or combinations thereof.
• Parenteral administration includes, but is not limited to, intravenous, intraarterial, intraperitoneal, subcutaneous, intramuscular, intrathecal, intraarticular, intracisternal and intraventricular.
• a therapeutically effective amount of the composition required for use in therapy varies with the length of time that activity is desired, and the age and the condition of the patient to be treated, among other factors, and is ultimately determined by the attendant physician. In general, however, doses employed for human treatment typically are in the range of about 0.001 mg/kg to about 500 mg/kg per day, for example about 1 ⁇ g/kg to about
• the total daily dosage is from about 1 to 100 mg, preferably from about 2 to 80 mg.
• the dosage regimen may be adjusted to provide the optimal therapeutic response.
• the desired dose may be conveniently administered in a single dose, or as multiple doses administered at appropriate intervals, for example as two, three, four or more subdoses per day.
• a composition of the invention may be administered to a subject to provide the subject with an antiestrogen in an amount of about 1 ⁇ g/kg to about 1 mg/kg body weight, for example about 1 ⁇ g/kg, about 25 ⁇ g/kg, about 50 ⁇ g/kg, about 75 ⁇ g/kg, about 100 ⁇ g/kg, about 125 ⁇ g/kg, about 150 ⁇ g/kg, about 175 ⁇ g/kg, about 200 ⁇ g/kg, about 225 ⁇ g/kg, about 250 ⁇ g/kg, about 275 ⁇ g/kg, about 300 ⁇ g/kg, about 325 ⁇ g/kg, about 350 ⁇ g/kg, about 375 ⁇ g/kg, about 400 ⁇ g/kg, about 425 ⁇ g/kg, about 450 ⁇ g/kg, about 475 ⁇ g/kg, about 500 ⁇ g/kg, about 525 ⁇ g/kg, about 550 ⁇ g/kg, about 575 ⁇ g
• compositions according to the present invention comprise frvms-clomiphene at a dosage between one mg to about 200 mg (although the determination of optimal dosages is with the level of ordinary skill in the art).
• the composition may comprise ?r ⁇ ms-clomiphene at a dosage of about 1 mg, 2 mg, 3, mg, 4 mg, 5 mg, 10 mg, 15 mg, 20 mg, 25 mg, 30 mg, 35 mg, 40 mg, 45 mg, 50 mg, 55 mg, 60 mg, 65 mg, 70 mg, 75 mg, 80 mg, 85 mg, 90 mg, 95 mg, 100 mg, 1 10 mg, 120 mg, 130 mg, 140 mg, 150 mg, 160 mg, 170 mg, 180 mg, 190 mg, 200 mg or there between.
• the composition may also comprise /r ⁇ ms-clomiphene and c/s-clomiphene at a ratio of about 71/29, 72/28, 73/27, 74/26, 75/25, 76/24, 77/23, 78/22, 79/21, 80/20, 81/19, 82/18, 83/17, 84/16, 85/15, 86/14, 87/13, 88/12, 89/1 1, 90/10, 91/9, 92/8, 93/7, 94/6, 95/5, 96/4, 97/3, 98/2, 99/1, 99.5/0.5 or there between.
• Analogs of the trans- and cis- isomers of clomiphene such as those described in Ernst, et al. supra are also useful in the practice of the present invention.
• compositions of the present invention may also be administered long-term.
• the compositions may be administered for a period of at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 1 1, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31 or more days.
• the compositions may also be administered for an administration period of at least 1 , 2, 3, 4, 5, 6, 7, 8, 9, 10, 1 1, 12 or more months.
• the compositions may also be administered for an administration period of at least 1, 2, 3, 4, 5, 6, 7 8, 9, 10 or more years.
• the composition may be administered daily or periodically such as every other day and the like.
• compositions of the present invention may also be administered intermittently.
• the compositions may be administered for an administration period of 1, 2, 3, 4, 5, or more weeks, followed by a period of discontinuance, followed by an administration period of 1, 2, 3, 4, 5 or more weeks, and so on.
• All of the references referred to herein are incorporated by reference in their entirety.
• the following Examples are meant to be illustrative of the invention and are not intended to limit the scope of the invention as set out is the appended claims.
• Enclomid resulted in an 8% decrease in serum cholesterol levels. Conversely, treatment with Zuclomid resulted in a 22% increase in serum cholesterol levels. Treatment with Clomid resulted in a slight increase in serum cholesterol levels.
• the opposite effect of Enclomid and Zuclomid on serum cholesterol levels is not unexpected given that the isomers have, alternatively, estrogen agonist or antagonist activity. These results indicate that Enclomid may be used for treating patients with high cholesterol levels. These results also indicate that Enclomid may be more benign than Zuclomid with respect to serum cholesterol if used chronically for increasing testosterone levels.
• AST and ALT No clearly adverse effects on liver function are apparent as judged by the enzymes AST and ALT. The trend in these values was a decrease with treatment. An increase in the level of enzymes in the serum would indicate liver damage. ALT/SGPT was out of range low at the end of the study for the Clomid group although the differences over the treatment period were not statistically significant. The changes with Enclomid and Zuclomid were within the normal range. AST is depressed in pregnancy; thus the action of an estrogen agonist such as Zuclomid in lowering the marginal AST level could be rationalized. Alkaline phosphatase (ALP) is also found in the liver and is elevated various disease states. The lowering of ALP argues further against hepatic damage.
• ALP Alkaline phosphatase
• BUN and BUN/creatinine were altered during the study in the Clomid and Enclomid groups, the lack of a definitive change in creatinine argues against renal dysfunction. A loss of glomerular filtration capacity would result in an increase in BUN. Decreased BUN occurs in humans due to poor nutrition (not likely in a controlled setting), or high fluid intake (presumably accompanied by edema). Also, despite an increase in total serum testosterone between day 0 and Day 12 with Enclomid, there were no differences between serum creatinine values, arguing against an increase in muscle mass over this short time interval.
• Serum sodium levels were lower than reference values for all animals throughout the study. Serum carbon dioxide was higher than reference values on day 12 for the Clomid and Zuclomid groups. Serum anion gap was lower for all animals throughout the study, paralleling the sodium results. Enclomid raised this parameter towards normal values. The electrolyte imbalances detected in the test animals throughout all treatment periods remains elusive but might be part of the same fluid derangement phenomenon suggested by the BUN results.
• Enclomid is more effective than Clomid or Zuclomid at enhancing total serum testosterone. Zuclomid is clearly not effective and that deficiency limits any use of Clomid for hypogonadism, particularly since the Zuclomid component of Clomid would predominate in the circulation over time given its longer half- life.
• Enclomid appeared to be relatively benign in all aspects when compared to Zuclomid and, often, even Clomid. This is particularly true when consideration is given to the trend of Enclomid to lower cholesterol, and liver enzymes as opposed to Zuclomid's trend to raise the same parameters. The surprising trend for Enclomid to raise the lymphocyte count may be useful for men with AIDS if it can be shown the CD4+ subpopulation of lymphocytes is not lowered or is enhanced.
• Subjects with fasting blood glucose levels between 1 10 and 125 mg/dl are given daily dosages of 1.5 mg/kg clomiphene, wherein the ratio of /r ⁇ r ⁇ -clomiphene to c ⁇ -clomiphene is greater than 71/29.
• Fasting blood glucose levels are monitored at regular intervals such that the dosage amount and dosage frequency may be adjusted to achieve therapeutic fasting blood glucose levels in the subject.
• Insulin sensitivity is assessed in subjects using, e.g., the hyperinsulinemic-euglycemic clamp as described in Defronzo et al., Am. J. Physiol. 237:E214-E223 (1979) and/or the homeostatic model assessment for insulin resistance (HOMA-IR) as described in Matthews et al., Diabetologia. 28:412-419 (1985).
• HOMA-IR homeostatic model assessment for insulin resistance
• Subjects with insulin resistance are given daily dosages of 1.5 mg/kg clomiphene, wherein the ratio of /r ⁇ r ⁇ -clomiphene to cw-clomiphene is greater than 71/29. Insulin sensitivity is monitored at regular intervals such that the dosage amount and dosage frequency may be adjusted to achieve therapeutic increases in insulin sensitivity in the subject.
• EXAMPLE 4 Method for Treating Diabetes Mellitus Type 2 by Administration of Trans-clomiphene and Mixtures of Trans-clomiphene and Cis-clomiphene at Ratios Greater Than 71/29
• Subjects diagnosed with diabetes mellitus type 2 are administered daily dosages of 1.5 mg/kg clomiphene, wherein the ratio of frvms-clomiphene to m-clomiphene is greater than 71/29.
• Glycemia, insulinemia, and optionally plasma triglyceride levels are monitored at regular intervals such that the dosage amount and dosage frequency may be adjusted to achieve therapeutic benefits in insulin responsiveness and/or blood glucose levels.
• a placebo controlled challenge study was conducted at the Advanced Biological Research, Inc. (ABR) Clinical Research Center in Ralphensack, New Jersey to compare orally administered AndroxalTM (/r ⁇ r ⁇ '-clomiphene) to Androgel® in hypogonadal men.
• Androgel® Solvay Pharmaceuticals, Inc.
• the study enrolled 62 hypogonadal men with testosterone levels less than 300 ng/dl (normal 298-1034 ng/dl) that were randomized into 6 different arms, three doses of AndroxalTM (12.5 mg, 25 mg, and 50 mg), placebo, and both high and low doses of Androgel®.
• Half of the men in each of the AndroxalTM and placebo arms were randomized into cohorts that underwent in-clinic sessions on days 1 and 14 to determine pharmacokinetic parameters for AndroxalTM as well as cyclical changes in testosterone.
• the placebo and AndroxalTM doses were administered in a double blind fashion.
• the Androgel® cream was administered in an open label fashion.
• the 50 mg dose of AndroxalTM raised mean total testosterone to 589 ⁇ 172 ng/dl after 15 days, a coefficient of variation (CV) of 29% and similar to the placebo group (36%).
• Androgel® 5G and 1OG yielded mean total testosterone values 473 ⁇ 289 ng/dl and 608 ⁇ 323 ng/dl, CVs of 61% and 53% respectively.
• Treatment with AndroxalTM produced a statistically significant increase in the serum levels of LH in the hypogonadal male subjects (FIG. 6). As in the case of total serum testosterone there was an unexpected continuation in the level of serum LH in the follow-up period (i.e., 7-10 days after cessation of daily oral treatment) where those levels remained high for the three doses of AndroxalTM. By comparison, treatment with AndroGel® initially decreased LH and after cessation there was an apparent rebound towards pre-treatment levels.
• Treatment with AndroxalTM also produced a statistically increase in the serum levels of FSH in the hypogonadal male subjects (FIG. 7).
• the pattern of increasing FSH is similar to that seen in the case of LH, that is, all doses of AndroxalTM boosts serum FSH which remains high during the follow-up period whereas AndroGel® suppresses the level of serum FSH and cessation of treatment allows serum FSH to rebound towards concentrations more similar to pre-treatment levels.
• DHT serum dihydroxytestosterone
• results of clinical chemistry parameters also indicated, unexpectedly, that men on AndroxalTM experienced a non-dose dependent reduction in triglycerides.
• the reduction in triglycerides averaged a decrease of 19.1% after two weeks of therapy. This compared to a 5.9% reduction for the placebo group and increases of 0.3% and 22% for the Androgel® 5G and 1OG respectively.
• AndroxalTM appears to raise total testosterone into the normal range in a highly consistent manner without abnormally high spikes in serum testosterone.
• frr ⁇ -clomiphene to treat men that suffer secondary hypogonadism offers a new approach that potentially could offset one of the major side effects of exogenous therapies such as Androgel®.
• Exogenous therapies provide negative feedback thereby shutting down FSH and LH production.
• FSH is an essential reproductive hormone and in the male stimulates spermatogenesis.
• a placebo controlled study was conducted to determine the effects of orally administered AndroxalTM (Yr ⁇ r ⁇ -clomiphene) and Androgel® on blood glucose levels.
• Androgel® Solvay Pharmaceuticals, Inc.
• Yr ⁇ r ⁇ -clomiphene Yr ⁇ r ⁇ -clomiphene
• Androgel® Solvay Pharmaceuticals, Inc.
• the study enrolled hypogonadal men (testosterone less than 300 ng/dl) with a broad range of body mass indices (BMI). Patients were randomized into 3 different arms, 50 mg dose of AndroxalTM, placebo, and high dose of Androgel®. The placebo and AndroxalTM doses were administered in a double blind fashion. The Androgel® cream was administered in an open label fashion. Fasting glucose levels were monitored in the patients immediately prior to treatment (baseline) and at regular intervals during the study. There were no side effects noted in either the AndroxalTM or Androgel® arms of the study that were different than placebo
• Figure 8 depicts the baseline blood glucose levels of each treatment group.
• the patients in each treatment group are separated on the graph according to BMI.
• Dark shaded bars depict baseline blood glucose in patients in each treatment group with BMI > 26 (EP300).
• Light shaded bars depict baseline blood glucose in patients in each treatment group with BMI ⁇ 27.
• baseline blood glucose in patients with BMI > 26 was significantly elevated in all treatment groups relative to patients with BMI ⁇ 27.
• Figure 9 depicts changes in serum glucose from baseline in the Androxal treatment group. The patients are separated on the graph according to BMI. Dark shaded bars depict changes in serum glucose from baseline in patients with BMI > 26 (EP300). Light shaded bars depict changes in serum glucose from baseline in patients with BMI ⁇ 27. As can be seen from Figure 9, treatment with Androxal was effective in lowering serum glucose levels in patients with BMI > 26 throughout the treatment period, with a reduction of nearly 24 mg/dl observed at the 3 and 4.5 month periods.
• Figure 10 depicts changes in serum glucose from baseline in the Androgel® and Placebo treatment groups in patients with BMI > 26 (EP300). Dark shaded bars depict changes in serum glucose from baseline in patients in the placebo group. Light shaded bars depict changes in serum glucose from baseline in patients in the Androgel® treatment group. As can be seen from Figure 10, no significant differences in serum glucose from baseline were observed in patients with BMI > 26 in either Androgel® or placebo treatment groups.
• AndroxalTM is surprisingly effective in reducing fasting glucose levels (and accompanying insulin resistance) in patients with low normal or below normal testosterone who have developed metabolic syndrome and demonstrates efficacy of AndroxalTM in treating metabolic syndrome and conditions associated therewith such as elevated glucose levels, elevated triglyceride levels, elevated, elevated cholesterol levels, insulin resistance, high blood pressure and obesity.
• administration of exogenous testosterone is ineffective in reducing glucose levels in patients with low normal or below normal testosterone who have developed metabolic syndrome.
• AndroxalTM is also expected to be effective in the treatment of diabetes mellitus type 2 in both male and female subjects.

Landscapes

• Health & Medical Sciences (AREA)
• Medicinal Chemistry (AREA)
• Diabetes (AREA)
• Veterinary Medicine (AREA)
• Public Health (AREA)
• General Health & Medical Sciences (AREA)
• Animal Behavior & Ethology (AREA)
• Chemical & Material Sciences (AREA)
• Life Sciences & Earth Sciences (AREA)
• Pharmacology & Pharmacy (AREA)
• Epidemiology (AREA)
• Bioinformatics & Cheminformatics (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• Organic Chemistry (AREA)
• General Chemical & Material Sciences (AREA)
• Chemical Kinetics & Catalysis (AREA)
• Obesity (AREA)
• Hematology (AREA)
• Engineering & Computer Science (AREA)
• Endocrinology (AREA)
• Emergency Medicine (AREA)
• Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
• Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Applications Claiming Priority (2)

Publications (1)

Family

ID=41404260

Family Applications (1)

Country Status (4)

Cited By (7)

Citations (4)

• 2009
  • 2009-11-03 TW TW098137209A patent/TWI458478B/zh not_active IP Right Cessation
  • 2009-11-03 TW TW103133928A patent/TW201500041A/zh unknown
  • 2009-11-05 CL CL2009002036A patent/CL2009002036A1/es unknown
  • 2009-11-06 AR ARP090104308A patent/AR074302A1/es unknown
  • 2009-11-06 WO PCT/US2009/063621 patent/WO2010054248A1/en active Application Filing

Patent Citations (4)

Also Published As

Similar Documents

Legal Events